Complete ENT (Otorhinolaryngology) question bank — ear, nose, throat, larynx, airway & head-neck — in explanation-first exam-topper style, with 72 diagrams.
12chapters144questions77High-Yield
THE CONCEPT
Allergic rhinitis is an IgE-mediated (type I hypersensitivity) inflammation of the nasal mucosa in response to inhaled allergens, characterised by sneezing, rhinorrhoea, nasal itching and congestion. It is very common and part of the atopic tendency (with asthma and eczema).
Allergic rhinitis: type I (IgE) mechanism
Sensitisation
allergen
APC
Th2
B → IgE
mastIgE-coated mast cell
Re-exposure
allergen cross-links IgE
degranulationhistamine + leukotrienes
EARLY (min): sneeze, itch,watery rhinorrhoea
LATE (hrs): eosinophils,congestion, hyperreactivity
Allergic rhinitis is a type I (IgE-mediated) hypersensitivity: first the allergen sensitises the person (allergen → antigen-presenting cell → Th2 → B cells make IgE, which coats mast cells); on re-exposure the allergen cross-links this IgE, degranulating the mast cell to release histamine and leukotrienes — an early phase (sneezing, itch, watery rhinorrhoea) and a late phase (eosinophilic congestion).
MECHANISM (type I hypersensitivity)
In sensitisation, an allergen (pollen, dust mite, danders, moulds) is processed by antigen-presenting cells → a Th2 response → B cells make allergen-specific IgE, which binds mast cells/basophils. On re-exposure the allergen cross-links this IgE, degranulating mast cells to release histamine, leukotrienes and prostaglandins — an early phase (minutes: sneezing, itch, watery rhinorrhoea, congestion) and a late phase (hours: eosinophilic inflammation, sustained congestion, hyper-responsiveness).
CLASSIFICATION (ARIA) & FEATURES
The ARIA classification grades it by duration (intermittent <4 days/week or <4 weeks vs persistent ≥4 days/week and ≥4 weeks) and severity (mild vs moderate-severe); the older split is seasonal (hay fever, pollens) vs perennial (dust mite, danders).
ARIA classification of allergic rhinitis
MILD
MODERATE-SEVERE
INTERMITTENT<4 days/wkor <4 wks
PERSISTENT≥4 days/wkand ≥4 wks
Moderate-severe = disturbed sleep / daily activity / sport / work-school, or troublesome symptoms
The ARIA classification grades allergic rhinitis by duration (intermittent vs persistent) and severity (mild vs moderate-severe, the latter defined by disturbed sleep, daily activities, sport, work/school or troublesome symptoms), and this grid guides the choice of treatment.
Paroxysmal sneezing, watery rhinorrhoea, nasal itching and congestion/obstruction, with itchy watery eyes (allergic conjunctivitis) and an itchy palate/throat.
Signs: pale, bluish, boggy, oedematous turbinates with clear discharge, an allergic salute/transverse nasal crease, allergic shiners, Dennie-Morgan lines, and mouth breathing (adenoid facies in children).
Associations: asthma, eczema, nasal polyps, sinusitis and otitis media with effusion.
DIAGNOSIS & MANAGEMENT
Diagnosis is clinical (history of triggers, seasonality, family atopy) with a skin-prick test/serum-specific IgE and a nasal smear (eosinophils). Management is stepwise: allergen avoidance, then pharmacotherapy — intranasal corticosteroids (the most effective, first-line for moderate-severe/persistent), antihistamines (oral 2nd-generation or intranasal), leukotriene antagonists (with asthma), short-term decongestants, ipratropium and saline — and allergen immunotherapy for refractory/specific-allergen disease, treating any comorbid asthma/conjunctivitis.
💡
CLINICAL PEARL: Allergic rhinitis = IgE-mediated (type I) nasal inflammation to inhaled allergens → sneezing, watery rhinorrhoea, nasal itch and congestion (+ itchy eyes); mast-cell histamine (early) + eosinophilic late phase. Classify by ARIA (intermittent/persistent × mild/moderate-severe). Signs: pale boggy turbinates, allergic salute/crease/shiners. Manage with allergen avoidance + intranasal steroids (most effective) + antihistamines ± LTRA/decongestant; immunotherapy if refractory. It is part of atopy (asthma/eczema).
WHY THE EARLY AND LATE PHASES MATTER
Understanding that allergic rhinitis has two phases — an early and a late response — explains both its symptoms and its treatment. The early phase, within minutes of allergen exposure, is driven by the histamine released from mast-cell degranulation and produces the immediate sneezing, itching and watery rhinorrhoea — the symptoms that antihistamines, which block histamine, relieve so well. Hours later, the late phase sets in as eosinophils and other inflammatory cells are recruited into the mucosa, producing sustained nasal congestion and a heightened reactivity that makes the nose more easily triggered by subsequent exposures. This late-phase inflammation is largely responsible for the persistent blockage that antihistamines do not relieve well, and it is why intranasal corticosteroids — which suppress the whole inflammatory cascade — are the most effective treatment, particularly for congestion. Appreciating the two phases thus clarifies why different drugs suit different symptoms.
WHY IT IS PART OF THE ATOPIC PICTURE
An important concept is that allergic rhinitis rarely exists in isolation but is one expression of a wider atopic tendency, and recognising this changes how the patient is assessed and managed. The same underlying predisposition to make IgE against common allergens also produces asthma, atopic dermatitis (eczema) and allergic conjunctivitis, so a patient with allergic rhinitis frequently has, or will develop, one or more of these. This has two practical consequences. First, the clinician should ask about and look for coexisting asthma and eczema, because treating the rhinitis can improve asthma control (the 'united airway'). Second, it explains the allergic march, in which eczema and food allergy in infancy give way to allergic rhinitis and asthma later in childhood. Seeing allergic rhinitis as part of a systemic atopic process, rather than a purely local nasal complaint, leads to more complete and effective care.
💊
KEY POINTS / DRUGS (viva)
Allergic rhinitis = type I (IgE) hypersensitivity: allergen → Th2 → IgE on mast cells; re-exposure → cross-link → histamine/leukotrienes; early phase (sneeze/itch/rhinorrhoea) + late phase (eosinophils/congestion).
ARIA: intermittent (<4 days/wk or <4 wks) vs persistent (≥4 days/wk and ≥4 wks); mild vs moderate-severe (sleep/activity/work-school/troublesome symptoms). Seasonal (pollen) vs perennial (dust mite/danders).
SOURCES: Dhingra — Diseases of Ear, Nose and Throat; Scott-Brown's Otorhinolaryngology.
THE CONCEPT
Vasomotor rhinitis (a type of non-allergic rhinitis) is chronic nasal symptoms — congestion and rhinorrhoea — due to an autonomic (parasympathetic) imbalance/hyperreactivity of the nasal mucosa to non-specific, non-allergic triggers, without evidence of allergy (negative allergy tests, no specific IgE).
PATHOPHYSIOLOGY & TRIGGERS
There is dysregulation of the autonomic control of the nasal vasculature and glands — an overactive parasympathetic (or reduced sympathetic) tone → vasodilation, congestion and increased secretion — triggered by non-allergic stimuli: changes in temperature/humidity, cold air, strong odours/perfumes/smoke, alcohol, spicy food (gustatory rhinitis), emotion, hormonal changes (pregnancy) and certain drugs.
CLINICAL FEATURES
Predominant nasal obstruction and watery rhinorrhoea.
Much less sneezing, itching and eye involvement than allergic rhinitis (a helpful distinction).
Perennial, with no seasonality or allergen link; usually in adults, with negative allergy tests.
ALLERGIC versus VASOMOTOR
Feature
Allergic
Vasomotor
Trigger
Specific allergen
Non-specific (temperature, odours)
Sneezing/itch
Prominent
Minimal
Eye symptoms
Common
Absent
Allergy tests
Positive
Negative
Main symptom
Sneeze/rhinorrhoea
Obstruction/rhinorrhoea
MANAGEMENT
Management is to avoid triggers and use intranasal corticosteroids, an intranasal anticholinergic (ipratropium, for rhinorrhoea) or intranasal antihistamine (azelastine), saline and short-term decongestants; oral antihistamines are less effective (it is not IgE-mediated). Turbinate reduction (for refractory obstruction) or, rarely, vidian neurectomy (for severe rhinorrhoea) are surgical options.
💡
CLINICAL PEARL: Vasomotor rhinitis = non-allergic rhinitis from autonomic (parasympathetic) hyperreactivity to non-specific triggers (temperature, odours, smoke, alcohol, spicy food, emotion) — with negative allergy tests. It gives predominant obstruction + watery rhinorrhoea, with much less sneezing/itch/eye symptoms than allergic rhinitis. Manage by avoiding triggers + intranasal steroid + ipratropium (rhinorrhoea)/azelastine; oral antihistamines are less effective; turbinate reduction/vidian neurectomy if refractory.
WHY DISTINGUISHING IT FROM ALLERGIC RHINITIS MATTERS
The practical importance of separating vasomotor from allergic rhinitis is that, although they can look similar, they respond to different treatments. Because vasomotor rhinitis is not IgE-mediated, the histamine-blocking oral antihistamines that work so well in allergic rhinitis are largely ineffective, and there is no allergen to avoid or to target with immunotherapy. Instead, treatment focuses on avoiding the non-specific triggers, using intranasal corticosteroids, and — for the prominent watery rhinorrhoea — an intranasal anticholinergic such as ipratropium, which blocks the parasympathetic drive responsible. Recognising the clues that point to a vasomotor rather than allergic cause — the absence of sneezing, itching and eye symptoms, the non-specific triggers, and above all the negative allergy tests — therefore directly changes management, and prevents the futile prescription of antihistamines and allergen avoidance for a condition that has no allergic basis.
A NOTE ON THE OTHER NON-ALLERGIC RHINITES
It helps to place vasomotor rhinitis within the wider family of non-allergic rhinites, since it is a diagnosis of exclusion that overlaps with several related conditions. Gustatory rhinitis (watery rhinorrhoea triggered by hot or spicy food), rhinitis of pregnancy (hormonally-driven congestion that resolves after delivery), drug-induced rhinitis (from certain antihypertensives, and rhinitis medicamentosa from decongestant overuse), occupational rhinitis (from workplace irritants) and NARES (non-allergic rhinitis with eosinophilia) all cause non-allergic nasal symptoms with negative allergy tests. Recognising these related entities matters because some have specific remedies — stopping a culprit drug, awaiting delivery, or removing an occupational exposure — whereas true vasomotor rhinitis, once these are excluded, is managed symptomatically. Approaching a patient with chronic non-allergic nasal symptoms by working through this list ensures a treatable specific cause is not mislabelled as idiopathic vasomotor rhinitis.
THE BOTTOM LINE
Vasomotor rhinitis is a non-allergic, autonomically-driven rhinitis presenting with obstruction and watery rhinorrhoea but little sneezing, itch or eye involvement and negative allergy tests, managed by trigger avoidance, intranasal steroids and ipratropium rather than the antihistamines and immunotherapy used for allergic disease.
A useful additional clue in practice is the response to treatment itself: a nose that fails to improve with antihistamines but settles with an intranasal steroid and ipratropium, in a patient with negative allergy tests and no seasonality, fits vasomotor rhinitis well, and this pragmatic 'therapeutic' distinction often confirms the diagnosis where the history alone leaves it uncertain.
💊
KEY POINTS / DRUGS (viva)
Vasomotor rhinitis = non-allergic rhinitis; autonomic (parasympathetic) hyperreactivity of nasal mucosa to non-specific triggers; negative allergy tests / no IgE.
Refractory: turbinate reduction (obstruction) or vidian neurectomy (severe rhinorrhoea, rare).
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
Allergy testing identifies the specific allergen(s) causing type I (IgE-mediated) allergic disease (rhinitis, asthma), to confirm the diagnosis and guide avoidance and immunotherapy.
Skin prick test
allergen +(wheal+flare)
allergen −
histamine (+ control)
saline (− control)
Prick allergen drop into skin → read at 15–20 min · wheal ≥3 mm larger than saline = positive
The skin-prick test: drops of standardised allergen extract are pricked into the skin and read at 15–20 minutes; a positive response is a wheal (with surrounding flare) at least 3 mm larger than the saline (negative) control, alongside a histamine positive control.
METHODS
Skin-prick test (SPT) — first-line, in-vivo: a drop of standardised allergen extract is placed on the forearm/back and the skin pricked through it; a positive response is a wheal and flare at 15–20 minutes (mast-cell histamine release), with a histamine positive control and a saline negative control; a wheal ≥3 mm larger than the negative control is positive. It is cheap, quick and sensitive, but antihistamines must be stopped beforehand and there is a small anaphylaxis risk.
Serum specific IgE (RAST/ImmunoCAP) — in-vitro: measures allergen-specific IgE in blood, used when SPT cannot be done (dermographism, severe eczema, on antihistamines, anaphylaxis risk, uncooperative patient); it carries no risk and is unaffected by drugs, but is more expensive and less immediate. Nasal provocation (allergen challenge) is reserved for specific cases, and total IgE/eosinophils are supportive but non-specific.
INTERPRETATION
WHY THE TEST MUST MATCH THE HISTORY
The most important principle in interpreting any allergy test is that a positive result confirms sensitisation, not necessarily clinical allergy, and the two must be reconciled with the patient's history. Many people have detectable IgE to an allergen — a positive skin prick or specific-IgE result — without ever developing symptoms on exposure; testing them indiscriminately therefore generates positives that are clinically meaningless and can lead to unnecessary avoidance advice. The test is only useful when it is used to confirm a suspicion raised by the history — for example, a patient whose symptoms flare in spring is tested for pollen, and a positive result then confirms the culprit. This is why allergy testing is described as a way of confirming, not screening for, allergy, and why results are always interpreted alongside the clinical picture rather than in isolation — a point examiners frequently emphasise.
CHOOSING BETWEEN SKIN-PRICK AND BLOOD TESTS
A practical skill is knowing when to choose the skin-prick test and when to use serum specific IgE, since each has its place. The skin-prick test is usually preferred first — it is cheap, quick, sensitive and gives an immediate visible result that the patient can see, and it can screen several allergens at once. However, it requires the patient to stop antihistamines beforehand (or the wheal is suppressed), needs healthy skin (so is unsuitable in severe eczema or dermographism), and carries a small risk of a systemic reaction. In these situations — a patient who cannot stop antihistamines, has widespread skin disease, or is at risk of anaphylaxis — the blood test (serum specific IgE) is chosen instead, as it is safe, unaffected by drugs and needs no skin, at the cost of being more expensive and slower. Matching the test to the patient's circumstances is the key judgement.
⚠️
DANGER / REMEMBER: Results must correlate with the clinical history — sensitisation is not the same as clinical allergy, so a positive test without corresponding symptoms is not diagnostic.
💡
CLINICAL PEARL: Allergy testing identifies the causative allergen in type I (IgE) disease. Skin-prick test (first-line, in-vivo): allergen drop + prick → wheal and flare at 15–20 min (wheal ≥3 mm > saline control = positive); stop antihistamines first; small anaphylaxis risk. Serum specific IgE (RAST/ImmunoCAP, in-vitro): when SPT is unsuitable (eczema, on antihistamines, anaphylaxis risk); safe and drug-independent. Results must correlate with the clinical history (sensitisation ≠ allergy).
💊
KEY POINTS / DRUGS (viva)
Allergy testing: identifies the causative allergen in type I (IgE) allergic disease to guide avoidance/immunotherapy.
Skin-prick test (first-line, in-vivo): standardised allergen drop pricked into skin; read at 15–20 min; wheal ≥3 mm > saline (negative) control = positive; histamine = positive control. Stop antihistamines first; small anaphylaxis risk.
Serum specific IgE (RAST/ImmunoCAP, in-vitro): when SPT unsuitable (dermographism, severe eczema, on antihistamines, anaphylaxis risk, uncooperative); no risk, drug-independent, costlier/slower. Also nasal provocation (special cases), total IgE/eosinophils (supportive). Must correlate with clinical history (sensitisation ≠ allergy).
🔑
KEY POINTS TO REMEMBER
Allergy testing identifies the causative allergen in type I (IgE) disease to guide avoidance/immunotherapy.
Skin-prick test (first-line, in-vivo): allergen drop + prick → wheal & flare at 15–20 min; wheal ≥3 mm > saline control = positive; histamine positive control.
SPT: cheap, quick, sensitive; stop antihistamines first; small anaphylaxis risk.
Serum specific IgE (RAST/ImmunoCAP, in-vitro): when SPT unsuitable (eczema, on antihistamines, anaphylaxis risk); safe, drug-independent, costlier.
Results must correlate with the clinical history — sensitisation is not the same as clinical allergy.
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
Allergen immunotherapy (desensitization/hyposensitization) is the administration of gradually increasing doses of the specific allergen to induce immune tolerance, reducing symptoms and medication need. It is the only disease-modifying treatment for allergic rhinitis (it alters the natural course).
MECHANISM
Repeated controlled allergen exposure shifts the immune response from Th2 toward Th1/T-regulatory, induces 'blocking' IgG antibodies, and reduces IgE and mast-cell/eosinophil reactivity → immune tolerance to the allergen.
ROUTES & INDICATIONS
Subcutaneous immunotherapy (SCIT) — injections, up-dosing then maintenance over about 3–5 years; effective, but with a risk of systemic reactions/anaphylaxis (given where resuscitation is available).
Sublingual immunotherapy (SLIT) — drops/tablets under the tongue; safer (home use), with fewer systemic reactions; for specific allergens (grass pollen, dust mite).
It is indicated for moderate-severe allergic rhinitis (± conjunctivitis/asthma) inadequately controlled by avoidance and pharmacotherapy, with a clearly identified single/few allergen(s) confirmed on testing (also for venom allergy).
CONTRAINDICATIONS & BENEFITS
WHY IT IS UNIQUELY DISEASE-MODIFYING
The feature that sets allergen immunotherapy apart from every other treatment for allergic rhinitis is that it is disease-modifying rather than merely symptom-suppressing, and understanding this explains its importance. All the drugs — antihistamines, intranasal steroids, decongestants — control symptoms only while they are being taken; stop them and the allergy returns unchanged. Immunotherapy, by contrast, retrains the immune system's response to the allergen — shifting it away from the Th2/IgE pattern toward tolerance — so that the underlying allergy itself is reduced. This is why its benefits are long-lasting, persisting for years after a completed course, and why it may actually alter the natural history of atopy — preventing new sensitisations and reducing progression from rhinitis to asthma. For a motivated patient with a well-defined allergen and troublesome disease, this potential for lasting change, rather than indefinite symptom control, is what makes the commitment of a multi-year course worthwhile.
BALANCING BENEFIT AGAINST THE RISK OF ANAPHYLAXIS
A crucial consideration in immunotherapy is the balance between its benefits and the risk of a systemic allergic reaction, which shapes how and to whom it is given. Because the treatment deliberately administers the very allergen the patient reacts to, there is an inherent risk of provoking a systemic reaction or even anaphylaxis — greatest with the injected (subcutaneous) route. This risk explains several practical rules: subcutaneous immunotherapy is given only where resuscitation facilities are available, with a period of observation after each dose; it is avoided in uncontrolled asthma (which makes any reaction more dangerous) and in patients on beta-blockers (which impair the treatment of anaphylaxis); and the safer sublingual route, with far fewer systemic reactions, can be taken at home. Weighing the substantial long-term benefit against this small but serious risk — and selecting patients and routes accordingly — is central to using immunotherapy safely.
A NOTE ON THE COMMITMENT INVOLVED
A practical point that shapes patient selection for immunotherapy is the considerable commitment it demands. Unlike a course of tablets or a spray, immunotherapy is a prolonged treatment lasting around three to five years, requiring regular clinic visits for subcutaneous injections (with a period of observation after each) or disciplined daily self-administration for the sublingual route. Benefit is not immediate — it builds over months — and premature discontinuation reduces the chance of the lasting tolerance that is the whole point of the treatment. For this reason it is offered to motivated patients with genuinely troublesome, well-defined allergic disease who understand and accept the duration and the small risks, rather than as a casual alternative to medication. Setting realistic expectations about the timescale and the need for persistence is therefore an important part of counselling, and helps ensure that those who embark on immunotherapy complete it and gain its durable benefit.
THE BOTTOM LINE
Allergen immunotherapy is the only disease-modifying treatment for allergic rhinitis, retraining the immune system toward tolerance over a multi-year course by the subcutaneous or safer sublingual route, offering lasting benefit and possible prevention of asthma in carefully selected patients.
⚠️
DANGER / REMEMBER: Avoid in severe/uncontrolled asthma, significant cardiac disease or those on beta-blockers, and during pregnancy (do not initiate); use cautiously in young children. Benefits are long-lasting (persist after stopping) and it may prevent new sensitisations and progression to asthma; risks are local and systemic reactions/anaphylaxis (mainly SCIT).
💡
CLINICAL PEARL: Allergen immunotherapy (desensitization) = graded increasing doses of the specific allergen → immune tolerance (Th2→Th1/Treg shift, blocking IgG); the only disease-modifying treatment for allergic rhinitis. Subcutaneous (SCIT — injections, 3–5 years, anaphylaxis risk) or sublingual (SLIT — tablets/drops, safer, home). For moderate-severe allergic rhinitis with a defined allergen inadequately controlled by drugs. Long-lasting; may prevent asthma. Avoid in uncontrolled asthma, on beta-blockers, or initiating in pregnancy.
Routes: subcutaneous (SCIT — injections, up-dosing then maintenance ~3–5 y; systemic/anaphylaxis risk, needs resuscitation facility) or sublingual (SLIT — tablets/drops, safer, home use).
Indications: moderate-severe allergic rhinitis (± conjunctivitis/asthma) with a defined allergen inadequately controlled by avoidance + drugs; venom allergy. Contraindications: uncontrolled/severe asthma, cardiac disease/beta-blockers, pregnancy (don't initiate), young children (relative). Long-lasting; may prevent asthma/new sensitisations.
🔑
KEY POINTS TO REMEMBER
Allergen immunotherapy = graded increasing doses of the specific allergen → immune tolerance; only disease-modifying treatment for allergic rhinitis.
Routes: subcutaneous (SCIT — injections, 3–5 years, anaphylaxis risk) or sublingual (SLIT — tablets/drops, safer, home).
Indicated for moderate-severe allergic rhinitis with a defined allergen inadequately controlled by drugs; also venom allergy.
Avoid in uncontrolled asthma, cardiac disease/beta-blockers, pregnancy (initiation); long-lasting benefit, may prevent asthma.
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat; Scott-Brown's Otorhinolaryngology.
THE CONCEPT
The drug treatment of allergic rhinitis is chosen by symptom pattern and severity (ARIA), targeting the underlying mediators and mechanisms.
DRUG CLASSES
Intranasal corticosteroids (fluticasone, mometasone, budesonide) — the most effective, first-line for moderate-severe/persistent; reduce all symptoms via broad anti-inflammatory action; take days–weeks for full effect; safe long-term (minimal absorption); side effects — local irritation, epistaxis, crusting.
Antihistamines (H1 blockers) — oral 2nd-generation (loratadine, cetirizine, fexofenadine — non-sedating, preferred) or intranasal (azelastine); rapid; good for sneezing, itch, rhinorrhoea and eye symptoms, less for congestion; 1st-generation (chlorpheniramine) is sedating — avoid.
Leukotriene receptor antagonists (montelukast) — modest; useful with coexisting asthma.
Decongestants — topical (oxymetazoline/xylometazoline) give rapid decongestion but only short-term (<5–7 days — risk of rhinitis medicamentosa); oral (pseudoephedrine).
Intranasal anticholinergic (ipratropium) — for watery rhinorrhoea; mast-cell stabilisers (sodium cromoglicate) — prophylactic, safe (children/pregnancy); saline; and short oral steroids as brief rescue.
CLINICAL PEARL: Allergic-rhinitis pharmacotherapy: intranasal corticosteroids = most effective (first-line for moderate-severe, cover all symptoms, take days); antihistamines (2nd-gen oral/intranasal — sneezing/itch/rhinorrhoea/eyes, less for congestion); LTRA (montelukast — with asthma); decongestants (topical short-term only <5–7 days — rhinitis medicamentosa risk); ipratropium (rhinorrhoea); cromoglicate (prophylactic). Step up by ARIA severity; immunotherapy if refractory.
WHY INTRANASAL STEROIDS ARE FIRST-LINE
It is worth understanding why intranasal corticosteroids are considered the single most effective treatment for allergic rhinitis and the preferred first-line agent for anything beyond mild disease. Unlike antihistamines, which block only the histamine-driven early-phase symptoms, intranasal steroids suppress the entire inflammatory process — both the early and, importantly, the late eosinophilic phase — so they relieve all the symptoms, including the nasal congestion that antihistamines leave largely untouched. Delivered directly to the nasal mucosa, they achieve a high local anti-inflammatory effect with minimal systemic absorption, making them safe for long-term use. Their main limitation is that they take several days of regular use to reach full effect, so patients must be told to use them consistently rather than as needed. Grasping that they treat the underlying inflammation, not just one mediator, explains their central place in management.
WHY DECONGESTANTS ARE ONLY FOR SHORT-TERM USE
A key safety principle in the drug treatment of rhinitis is that topical (intranasal) decongestants must be used only briefly — for no more than about five to seven days — and understanding why prevents a common iatrogenic problem. These sympathomimetic sprays work rapidly by constricting the nasal blood vessels to relieve congestion, which makes them tempting for ongoing use. However, with continued application the vessels become tolerant and there is a rebound vasodilation and swelling when each dose wears off, so the nose becomes more blocked, prompting more frequent use — the vicious cycle of rhinitis medicamentosa and decongestant dependence. This is why they are reserved for short-term relief (for example, at the start of treatment while an intranasal steroid takes effect) and never for maintenance, and why patients are explicitly warned about the time limit. The contrast with intranasal steroids — safe for long-term use — is an important teaching point.
A NOTE ON COMBINING AND STEPPING TREATMENT
An important practical principle is that these drug classes are combined and stepped according to severity rather than used in isolation, because they act on different parts of the allergic response. For mild, intermittent symptoms an antihistamine alone (with allergen avoidance) often suffices, targeting the histamine-driven sneezing and itch. For moderate-severe or persistent disease an intranasal corticosteroid becomes the backbone of treatment, and an antihistamine (oral or intranasal) can be added for breakthrough sneezing and eye symptoms, ipratropium for stubborn watery rhinorrhoea, and a short course of a decongestant or oral steroid to gain rapid initial control. A leukotriene antagonist is a useful add-on, especially when asthma coexists. This flexible, step-up (and step-down) approach — escalating when symptoms are poorly controlled and simplifying when they settle — mirrors the ARIA framework and allows treatment to be tailored to each patient's pattern and severity of disease.
THE BOTTOM LINE
The pharmacotherapy of allergic rhinitis is led by intranasal corticosteroids (the most effective, treating all symptoms) with antihistamines, leukotriene antagonists, ipratropium, cromoglicate and short-term decongestants added and stepped by ARIA severity, and immunotherapy reserved for refractory disease.
💊
KEY POINTS / DRUGS (viva)
Intranasal corticosteroids (fluticasone/mometasone/budesonide): MOST effective, first-line moderate-severe; all symptoms; take days–weeks; safe long-term (local: irritation/epistaxis/crusting).
Antihistamines: oral 2nd-gen (loratadine/cetirizine/fexofenadine, non-sedating) or intranasal (azelastine) — sneezing/itch/rhinorrhoea/eyes, less congestion; avoid sedating 1st-gen (chlorpheniramine). LTRA (montelukast) — modest, with asthma.
Decongestants: topical oxymetazoline/xylometazoline ONLY <5–7 days (rhinitis medicamentosa), oral pseudoephedrine. Ipratropium (rhinorrhoea); sodium cromoglicate (prophylactic, safe children/pregnancy); saline; short oral steroid (rescue). Step up by ARIA; immunotherapy if refractory.
🔑
KEY POINTS TO REMEMBER
Intranasal corticosteroids = most effective, first-line for moderate-severe/persistent; cover all symptoms; take days for full effect.
Antihistamines (2nd-gen oral/intranasal): sneezing, itch, rhinorrhoea, eye symptoms; less effective for congestion; avoid sedating 1st-gen.
LTRA (montelukast): modest, useful with asthma; ipratropium for rhinorrhoea; cromoglicate prophylactic (safe in children/pregnancy).
Topical decongestants: rapid but only short-term (<5–7 days) — risk of rhinitis medicamentosa.
Step up by ARIA severity (antihistamine → intranasal steroid ± add-ons); immunotherapy if refractory.
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat; ARIA guidelines.
THE CONCEPT
Rhinitis medicamentosa is rebound nasal congestion caused by the prolonged/overuse of topical nasal decongestants (oxymetazoline, xylometazoline — sympathomimetics) beyond the recommended few days (~5–7 days).
MECHANISM & FEATURES
Prolonged vasoconstriction leads to downregulation/tachyphylaxis of alpha-adrenoceptors plus rebound vasodilation/oedema → worsening congestion, so the patient uses more decongestant — a vicious cycle of dependence. Features are persistent nasal blockage, decongestant dependence and a boggy, congested mucosa (it can also be caused by cocaine and some antihypertensives).
MANAGEMENT
Management is to stop the topical decongestant (the key step), substitute an intranasal corticosteroid (to settle the rebound) ± a short oral steroid, and use saline; withdrawal one nostril at a time may help. Prevention is limiting decongestant use to under a week.
A NOTE ON WHY IT IS SO EASILY OVERLOOKED
Rhinitis medicamentosa is important because it is a common, entirely preventable, but frequently missed cause of persistent nasal blockage. Patients often start a topical decongestant for a cold or an episode of congestion, find that it works dramatically, and — not realising the danger — continue using it for weeks or months. As the rebound congestion sets in, they interpret their worsening blockage as a reason to keep using the spray, unaware that the spray itself is now the cause. The diagnosis is easily overlooked unless the clinician specifically asks about over-the-counter nasal spray use, which patients may not think to mention. Recognising the pattern — chronic congestion in someone dependent on a decongestant spray — and simply stopping the spray (with an intranasal steroid to ease the withdrawal) resolves a problem that might otherwise be investigated and treated as intractable rhinitis, which is why awareness of it is so valuable.
THE BOTTOM LINE
Rhinitis medicamentosa is preventable rebound congestion from overusing topical decongestants, treated by stopping the spray and substituting an intranasal steroid.
A further practical point is that withdrawal can be difficult because the rebound congestion is worst in the first days after stopping, so patients are supported through this period with an intranasal corticosteroid and saline, reassured that the blockage will settle, and sometimes advised to stop one nostril at a time to keep an airway while the other recovers — measures that improve the chance of successfully breaking the dependence.
It is also worth noting that awareness of this condition has practical public-health value, since these decongestant sprays are sold over the counter and widely used without medical advice, so counselling patients about the strict time limit whenever such a spray is recommended is a simple way to prevent a problem that is far easier to avoid than to treat.
🔑
KEY POINTS TO REMEMBER
Rhinitis medicamentosa = rebound nasal congestion from prolonged overuse of topical decongestants (oxymetazoline/xylometazoline) beyond ~5–7 days.
Mechanism: alpha-adrenoceptor downregulation/tachyphylaxis + rebound vasodilation/oedema → more congestion → more decongestant (vicious cycle).
Rx: STOP the decongestant (key), intranasal corticosteroid ± short oral steroid, saline; prevent by limiting decongestants to <1 week.
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
Allergic rhinitis (especially in children) produces several characteristic physical signs that support the diagnosis on examination.
Nasal signs of allergy
allergic shiners
Dennie-Morgan lines
transverse nasal crease
Allergic salute (rubbing nose upward) → the transverse crease
The nasal signs of allergy, especially in children: the allergic salute (rubbing the itchy nose upward) that produces a transverse nasal crease, allergic shiners (dark under-eye venous congestion) and Dennie-Morgan lines under the lower lids.
THE SIGNS
Allergic salute — the child rubs the itchy nose upward with the palm — leading to a transverse nasal crease (a horizontal line across the lower nose).
Allergic shiners — dark circles/venous congestion under the eyes; and Dennie-Morgan lines — creases under the lower eyelids.
Mouth breathing → adenoid facies (long face, open mouth) in chronic cases.
Pale, bluish, boggy, oedematous nasal mucosa with clear watery discharge; a cobblestone posterior pharyngeal wall (lymphoid hyperplasia) and a high-arched palate.
A NOTE ON THEIR DIAGNOSTIC VALUE
These physical signs are worth knowing because they allow allergic rhinitis to be recognised at a glance, particularly in children who may not give a clear history. A child with the habitual upward rubbing of the nose (the allergic salute), a visible transverse crease across the nose, dark allergic shiners and Dennie-Morgan folds beneath the eyes presents an almost diagnostic picture of chronic nasal allergy before any test is done. Spotting them prompts the right questions about triggers, seasonality and family atopy, and points toward examination of the nasal mucosa (typically pale and boggy) and consideration of coexisting eczema or asthma. Because they are simple, cost-free observations that can be made across the consulting room, these allergic signs are a genuinely useful part of the clinical assessment and a favourite of examiners asking how allergic rhinitis can be recognised on inspection.
THE BOTTOM LINE
The nasal signs of allergy — the allergic salute and transverse crease, allergic shiners and Dennie-Morgan lines — allow allergic rhinitis to be recognised on inspection, especially in children.
A further point is that these signs, while highly suggestive, are not exclusive to allergy and must be interpreted alongside the history and, where needed, allergy testing, since chronic nasal obstruction from any cause can produce mouth breathing and adenoid facies, and dark under-eye circles have other explanations — so the signs raise the suspicion of allergic rhinitis rather than proving it.
It is also worth noting that the presence of these allergic signs in a child should prompt a look for coexisting atopic conditions, since the same underlying tendency often produces eczema and asthma, so a thorough assessment of an allergic child extends beyond the nose to the skin and chest.
🔑
KEY POINTS TO REMEMBER
Allergic salute (rubbing the nose upward) → transverse nasal crease across the lower nose.
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
Samter's triad is a triad of (1) asthma, (2) nasal polyps (recurrent, eosinophilic) and (3) aspirin/NSAID sensitivity, also called aspirin-exacerbated respiratory disease (AERD).
MECHANISM & FEATURES
Aspirin/NSAIDs inhibit cyclooxygenase (COX), shunting arachidonic acid down the lipoxygenase pathway → overproduction of cysteinyl leukotrienes → bronchospasm, rhinorrhoea and nasal congestion (a pharmacological/pseudo-allergic reaction, not a true IgE allergy). Features are adult-onset asthma, chronic rhinosinusitis with recurrent nasal polyps, and severe reactions (bronchospasm, rhinorrhoea, flushing) on taking aspirin/NSAIDs.
MANAGEMENT
Management is to avoid aspirin/NSAIDs, treat the polyps/rhinosinusitis (intranasal + oral steroids, FESS), use leukotriene receptor antagonists (montelukast), and consider aspirin desensitization in specialist settings.
A NOTE ON WHY AVOIDING NSAIDS IS ESSENTIAL
The most important practical message of Samter's triad is that, in these patients, aspirin and other NSAIDs can provoke severe, even life-threatening, bronchospasm and must be strictly avoided. Because the reaction is pharmacological — stemming from the way these drugs block cyclooxygenase and shunt arachidonic acid toward leukotriene production — it is triggered by the whole class of NSAIDs, not just aspirin, so all of them are dangerous. This is why every patient with the combination of asthma and nasal polyps should be asked about aspirin/NSAID reactions and warned to avoid these drugs (using paracetacetamol or a selective COX-2 inhibitor for pain instead, under guidance). The same leukotriene mechanism also explains why leukotriene receptor antagonists such as montelukast are particularly useful in these patients, and why aspirin desensitisation is possible in specialist hands — making an understanding of the mechanism directly relevant to safe management.
THE BOTTOM LINE
Samter's triad (asthma, nasal polyps, aspirin/NSAID sensitivity) is a leukotriene-driven pseudo-allergy in which NSAIDs must be avoided and leukotriene antagonists are especially useful.
A further point is that the nasal polyps of Samter's triad are typically severe, eosinophilic and prone to recur even after surgery, so these patients often need ongoing medical treatment with intranasal and occasional oral corticosteroids and leukotriene antagonists, and represent one of the groups in whom newer biologic therapies targeting type-2 inflammation are increasingly used for difficult, recurrent disease.
It is also worth noting that the diagnosis is essentially clinical, made from the history of the three components together, and that formal aspirin challenge to confirm sensitivity is undertaken only in specialist centres because of the risk of provoking a severe reaction — so for most patients simple avoidance and recognition of the triad suffice.
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
The Gell and Coombs classification divides immune hypersensitivity into four types (mnemonic ACID).
Gell & Coombs hypersensitivity (ACID)
Type I — Immediate (IgE)
Allergen → IgE on mast cells→ histamine (minutes)
Allergic rhinitis, anaphylaxis,asthma, urticaria
Type II — Cytotoxic (IgG/IgM)
Antibody vs cell-surface antigen→ cell destruction
Haemolytic anaemia, transfusionreaction, Goodpasture
Type III — Immune complex
Antigen-antibody complexesdeposit → inflammation
Serum sickness, SLE,post-strep GN
Type IV — Delayed (T-cell)
Sensitised T cells (24–72 h)
Contact dermatitis, TB (Mantoux),transplant rejection
The Gell & Coombs classification of hypersensitivity (mnemonic ACID): Type I immediate/IgE (allergic rhinitis, anaphylaxis), Type II cytotoxic/antibody, Type III immune-complex, and Type IV delayed/T-cell. Allergic rhinitis is the classic Type I reaction.
THE FOUR TYPES
Type I (immediate, IgE-mediated) — allergen → IgE on mast cells → degranulation (histamine) within minutes → anaphylaxis, allergic rhinitis, asthma, urticaria.
Type II (antibody-mediated, cytotoxic) — IgG/IgM against cell-surface antigens → cell destruction (complement/ADCC) → haemolytic anaemia, transfusion reactions, Goodpasture.
Type III (immune-complex) — antigen-antibody complexes deposit → complement/inflammation → serum sickness, SLE, post-streptococcal glomerulonephritis.
Type IV (delayed, cell-mediated, T-cell) — sensitised T cells (24–72 h) → contact dermatitis, TB (Mantoux), transplant rejection.
Allergic rhinitis is a Type I reaction.
A NOTE ON WHY THE CLASSIFICATION IS USEFUL
The Gell and Coombs classification is worth learning because it provides a simple framework that links the mechanism of a reaction to its timing, its mediators and its clinical examples — which in turn guides diagnosis and treatment. Knowing that allergic rhinitis is a Type I, IgE-mediated, immediate reaction immediately explains why it responds within minutes to allergen exposure, why it is diagnosed by IgE-based tests (skin prick, specific IgE), and why antihistamines and mast-cell stabilisers help. Contrasting it with the other types — the antibody-mediated cytotoxic (II), immune-complex (III) and delayed T-cell (IV) reactions — clarifies why conditions such as contact dermatitis (Type IV) behave so differently, appearing after a day or two and being diagnosed by patch rather than prick testing. This mechanistic map, captured by the mnemonic ACID, is a foundational piece of immunology that recurs throughout medicine, which is why it is so frequently examined.
THE BOTTOM LINE
The Gell & Coombs classification (ACID) links each hypersensitivity type to its mechanism and examples, with allergic rhinitis the classic Type I, IgE-mediated reaction.
A further point worth remembering is that a single disease can involve more than one type of hypersensitivity, and that the classification, though a useful teaching framework, is a simplification of the real immunology; nonetheless, assigning a condition to its predominant type — as with allergic rhinitis being Type I — remains a reliable guide to how it presents and how it is investigated and treated.
It is also worth noting that the timing of a reaction is one of the most useful bedside clues to its type: an immediate reaction within minutes suggests Type I, whereas one appearing a day or two after exposure suggests the delayed, T-cell-mediated Type IV — a distinction that guides both diagnosis and the choice of confirmatory test.
🔑
KEY POINTS TO REMEMBER
Gell & Coombs (ACID): Type I Anaphylactic (IgE), II Cytotoxic (IgG/IgM), III Immune-complex, IV Delayed (T-cell).
Type I (immediate, IgE, mast cells): anaphylaxis, allergic rhinitis, asthma, urticaria — minutes.
Type II: antibody vs cell-surface antigen (haemolysis); Type III: immune complexes (serum sickness, SLE); Type IV: T-cell delayed (contact dermatitis, TB, rejection).
Allergic rhinitis is the classic Type I hypersensitivity reaction.
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat; Immunology.
THE CONCEPT
Allergic fungal rhinosinusitis (AFRS) is a form of chronic rhinosinusitis caused by an allergic (hypersensitivity) response to fungi (Aspergillus, or dematiaceous fungi such as Bipolaris/Curvularia) colonising the sinuses — not an invasive infection (the fungus does not invade tissue). It occurs in atopic, immunocompetent (often young) patients.
FEATURES & DIAGNOSIS
Features are chronic rhinosinusitis with nasal polyps and thick tenacious 'allergic mucin' (peanut-butter-like, eosinophil-rich with fungal hyphae), often unilateral, that may expand/erode sinus walls (proptosis). The Bent & Kuhn criteria include type I hypersensitivity, nasal polyps, characteristic CT (hyperattenuation), eosinophilic mucin with fungi and a positive fungal stain.
MANAGEMENT
Management is surgery (FESS — to remove the mucin/polyps and ventilate the sinuses) plus post-operative intranasal/oral corticosteroids and treatment of the allergy (± immunotherapy); antifungals have a limited role and recurrence is common. It must be distinguished from invasive fungal sinusitis (immunocompromised, tissue invasion, life-threatening).
A NOTE ON DISTINGUISHING IT FROM INVASIVE DISEASE
The single most important distinction to grasp with allergic fungal rhinosinusitis is that it is utterly different from invasive fungal sinusitis, despite both involving fungi in the sinuses. In AFRS the fungus merely colonises the sinus and provokes an allergic reaction in an immunocompetent person — it does not invade the tissues, so although it can be locally expansile and troublesome, it is not immediately life-threatening and is treated with surgery and steroids. Invasive fungal sinusitis, by contrast, occurs in the immunocompromised (poorly-controlled diabetics, neutropenic or transplant patients), where the fungus invades blood vessels and tissue, causing rapid necrosis that can spread to the orbit and brain and is often fatal without urgent surgical debridement and systemic antifungals. Confusing the two would be dangerous, which is why recognising the host (immunocompetent vs immunocompromised) and whether there is tissue invasion is the crucial step in managing any fungal sinus disease.
THE BOTTOM LINE
Allergic fungal rhinosinusitis is a non-invasive allergic reaction to sinus fungi in immunocompetent patients, treated with surgery and steroids, and must be distinguished from life-threatening invasive fungal sinusitis.
A further point is that, because the fungus is not invasive and the problem is essentially an exuberant allergic and inflammatory response, the aim of treatment is to remove the antigenic fungal mucin surgically and then suppress the inflammation medically, rather than to eradicate the fungus with antifungals — which is why steroids and surgery, not antifungal drugs, are the mainstays and why the condition tends to recur if the inflammation is not controlled.
🔑
KEY POINTS TO REMEMBER
AFRS = chronic rhinosinusitis from an allergic response to fungi colonising the sinuses (NOT invasive); atopic, immunocompetent patients.
CRS with nasal polyps + thick eosinophilic 'allergic mucin' (with fungal hyphae), often unilateral; may expand/erode sinus walls.
Bent & Kuhn criteria (type I hypersensitivity, polyps, characteristic CT, eosinophilic mucin with fungi, positive fungal stain).
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
The allergic march is the typical progression (natural history) of atopic/allergic diseases through childhood in a characteristic sequence.
The allergic march
infancyearly childhoodlater childhood →
atopic dermatitis
food allergy
allergic rhinitis
asthma
Eczema & food allergy in infancy → allergic rhinitis & asthma later (the atopic tendency)
The allergic march: the typical progression of atopic disease through childhood — atopic dermatitis (eczema) and food allergy in infancy, followed by allergic rhinitis and asthma later — reflecting the underlying atopic (IgE) tendency.
THE SEQUENCE & SIGNIFICANCE
It begins with atopic dermatitis (eczema) and food allergy in infancy, followed by allergic rhinitis and asthma in later childhood, reflecting the underlying atopic tendency (a genetic predisposition to IgE responses). Its significance is that early atopic dermatitis/food allergy predicts later respiratory allergy, and understanding it may guide prevention (early allergen introduction, skin-barrier care, and allergen immunotherapy to prevent progression to asthma). A child with eczema is at risk of developing allergic rhinitis and asthma.
A NOTE ON ITS IMPLICATIONS FOR PREVENTION
The allergic march is important not just as a description of how atopic disease evolves but because it raises the possibility of intervening early to change the course. If infant eczema and food allergy reliably herald later allergic rhinitis and asthma, then identifying these at-risk children early opens the door to preventive strategies — an area of active research and practice. Measures under study or in use include careful skin-barrier care and the early, controlled introduction of allergenic foods to reduce food allergy, and, notably, allergen immunotherapy in children with established allergic rhinitis, which may reduce their progression to asthma. Understanding the march therefore transforms it from a fatalistic sequence into a window of opportunity: recognising a child at the start of the march allows monitoring for, and potentially prevention of, the more serious respiratory allergy that might otherwise follow — which is the key clinical reason the concept matters.
THE BOTTOM LINE
The allergic march — eczema and food allergy giving way to allergic rhinitis and asthma — identifies at-risk children early and offers a window for preventive intervention.
A further point is that not every child follows the full sequence and the march is a tendency rather than an inevitability, but recognising a child who has begun it — typically an infant with eczema and food allergy — usefully alerts the clinician and family to watch for the later emergence of allergic rhinitis and asthma and to seek treatment early when they appear.
It is also worth noting that the concept underlines the value of taking a careful allergy and family history in any atopic child, since knowing that eczema and food allergy may presage respiratory allergy encourages appropriate monitoring and early treatment rather than treating each condition as it arises in isolation.
🔑
KEY POINTS TO REMEMBER
Allergic march = the typical childhood progression of atopic disease.
Reflects the underlying atopic tendency (genetic predisposition to IgE responses).
Early eczema/food allergy predicts later respiratory allergy; may guide prevention (immunotherapy may prevent progression to asthma).
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.
THE CONCEPT
Turbinate hypertrophy is enlargement of the (usually inferior) nasal turbinates causing nasal obstruction.
CAUSES & FEATURES
Causes include chronic/allergic/vasomotor rhinitis (mucosal ± bony hypertrophy), compensatory enlargement on the concave side of a deviated septum, and rhinitis medicamentosa. Features are nasal blockage (which may alternate with the nasal cycle), often bilateral, with enlarged turbinates on rhinoscopy that shrink with a decongestant if the component is mucosal.
MANAGEMENT
Management is to treat the cause (intranasal steroids for allergic rhinitis — a decongestant response indicates a mucosal component), and to perform surgical turbinate reduction for refractory obstruction (submucosal diathermy/radiofrequency, submucosal resection, partial turbinectomy or outfracture). It is important to preserve enough turbinate (over-resection risks 'empty nose syndrome'), and it is often combined with septoplasty.
A NOTE ON PRESERVING TURBINATE FUNCTION
A crucial principle in turbinate surgery is that the turbinates should be reduced, not removed wholesale, because they serve an essential physiological function. The turbinates warm, humidify and filter inspired air and regulate nasal airflow, so although an enlarged inferior turbinate causes troublesome obstruction, excising too much of it can paradoxically leave the patient worse off. Over-resection produces the distressing 'empty nose syndrome', in which a widely patent but non-functioning nose feels persistently blocked, dry and uncomfortable — a difficult, largely irreversible complication. This is why modern turbinate procedures favour tissue-preserving techniques (submucosal diathermy, radiofrequency or submucosal resection, or simply outfracturing) that reduce the bulk while preserving the mucosal surface and function, rather than radical turbinectomy. The lesson — relieve the obstruction while preserving enough functioning turbinate — mirrors the conservative, function-sparing philosophy seen throughout modern nasal surgery.
THE BOTTOM LINE
Turbinate hypertrophy causing obstruction is managed by treating the cause and, if refractory, by tissue-preserving turbinate reduction that avoids the empty nose syndrome of over-resection.
A further point is that, because turbinate enlargement is so often secondary to an underlying rhinitis, medical treatment of that rhinitis (particularly intranasal corticosteroids for allergic disease) is tried first, and surgery is reserved for genuine, persistent obstruction that fails to respond — and is frequently combined with correction of a coexisting septal deviation, since the two commonly occur together and both contribute to the blockage.
It is also worth noting that the nasal cycle — the normal alternating congestion and decongestion of the two sides every few hours — can make turbinate-related obstruction feel as though it shifts from side to side, a normal phenomenon that becomes noticeable only when the turbinates are enlarged and the airway is already marginal.
🔑
KEY POINTS TO REMEMBER
Turbinate hypertrophy = enlargement of the (usually inferior) turbinates → nasal obstruction.
Causes: chronic/allergic/vasomotor rhinitis, compensatory (concave side of a DNS), rhinitis medicamentosa.
Nasal blockage (may alternate — nasal cycle), often bilateral; shrinks with decongestant if mucosal.
Rx: treat the cause (intranasal steroids); surgical turbinate reduction (diathermy/radiofrequency, submucosal resection, partial turbinectomy, outfracture) if refractory — preserve enough turbinate (avoid empty nose syndrome).
📚
SOURCES: Dhingra — Diseases of Ear, Nose and Throat.